Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$131.49 USD

131.49
142,467

-0.94 (-0.71%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $131.54 +0.05 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings

by Zacks Equity Research

With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm

by Zacks Equity Research

Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.

Integer (ITGR) Down 2.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision (EYE) Rides on Positive Comps Amid Cost Woes

by Zacks Equity Research

National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.

STERIS (STE) Margin Pressure Hurts, Strategic Growth High

by Zacks Equity Research

Mounting operating expenses are weighing on the bottom line of STERIS (STE).

TeleFlex Announces Multiple Positive Outcomes on UroLift

by Zacks Equity Research

A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.

All You Need to Know About Integer (ITGR) Rating Upgrade to Strong Buy

by Zacks Equity Research

Integer (ITGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 22nd

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms

by Zacks Equity Research

Abbott's (ABT) EPD business operates in emerging geographies like India, Russia, China and Latin America.

Phibro Animal Solid on Global Prospects, Currency Woes Ail

by Zacks Equity Research

Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.

Edwards Lifesciences (EW) Looks Good: Stock Adds 6.2% in Session

by Zacks Equity Research

Edwards Lifesciences (EW) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Here's Why You Should Invest in Integer Holdings (ITGR) Stock

by Zacks Equity Research

Integer Holdings (ITGR) is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

Henry Schein's New Buyout to Boost Dental Technology Business

by Zacks Equity Research

Henry Schein (HSIC) expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 19th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Zimmer Biomet Solid on Global Prospects Despite Price Pressure

by Zacks Equity Research

Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.

Myriad's myPath Melanoma Test Awarded Medicare Coverage

by Zacks Equity Research

The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.

Align Technology (ALGN) Partners With Digital Smile Design

by Zacks Equity Research

Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.

Boston Scientific's WATCHMAN FLX LAAC Device Gets CE Mark

by Zacks Equity Research

Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.

HOLX vs VAR: Which MedTech Stock is a Better Investment Pick?

by Zacks Equity Research

Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.

QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test

by Zacks Equity Research

QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) is currently focusing on improving clinical quality.

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

by Zacks Equity Research

Bio-Rad (BIO) seeing solid revenue growth in geographies like Americas and Asia Pacific buoys optimism.

HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?

by Zacks Equity Research

DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 1st

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday